Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.
Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland.
Eur J Clin Nutr. 2023 Oct;77(10):989-997. doi: 10.1038/s41430-023-01303-w. Epub 2023 Jul 7.
Serum albumin concentrations are frequently used to monitor nutritional therapy in the hospital setting but supporting studies are largely lacking. Within this secondary analysis of a randomized nutritional trial (EFFORT), we assessed whether nutritional support affects short-term changes in serum albumin concentrations and whether an increase in albumin concentration has prognostic implications regarding clinical outcome and response to treatment.
We analyzed patients with available serum albumin concentrations at baseline and day 7 included in EFFORT, a Swiss-wide multicenter randomized clinical trial that compared individualized nutritional therapy with usual hospital food (control group).
Albumin concentrations increased in 320 of 763 (41.9%) included patients (mean age 73.3 years (SD ± 12.9), 53.6% males) with no difference between patients receiving nutritional support and controls. Compared with patients that showed a decrease in albumin concentrations over 7 days, those with an increase had a lower 180-day mortality [74/320 (23.1%) vs. 158/443 (35.7%); adjusted odds ratio 0.63, 95% CI 0.44 to 0.90; p = 0.012] and a shorter length of hospital stay [11.2 ± 7.3 vs. 8.8 ± 5.6 days, adjusted difference -2.2 days (95%CI -3.1 to -1.2)]. Patients with and without a decrease over 7 days had a similar response to nutritional support.
Results from this secondary analysis indicate that nutritional support did not increase short-term concentrations of albumin over 7 days, and changes in albumin did not correlate with response to nutritional interventions. However, an increase in albumin concentrations possibly mirroring resolution of inflammation was associated with better clinical outcomes. Repeated in-hospital albumin measurements in the short-term is, thus, not indicated for monitoring of patients receiving nutritional support but provides prognostic information.
ClinicalTrials.gov Identifier: NCT02517476.
血清白蛋白浓度常用于监测医院环境中的营养治疗,但支持性研究大多缺乏。在这项随机营养试验(EFFORT)的二次分析中,我们评估了营养支持是否会影响血清白蛋白浓度的短期变化,以及白蛋白浓度的增加是否对临床结局和治疗反应有预后意义。
我们分析了 EFFORT 中基线和第 7 天有可用血清白蛋白浓度的患者,这是一项瑞士多中心随机临床试验,比较了个体化营养治疗与常规医院饮食(对照组)。
在纳入的 763 例患者中有 320 例(41.9%)白蛋白浓度升高(平均年龄 73.3 岁(SD±12.9),53.6%为男性),接受营养支持的患者与对照组之间无差异。与白蛋白浓度在 7 天内下降的患者相比,白蛋白浓度升高的患者 180 天死亡率较低[74/320(23.1%)vs. 158/443(35.7%);调整后的优势比 0.63,95%置信区间 0.44 至 0.90;p=0.012],住院时间较短[11.2±7.3 天 vs. 8.8±5.6 天,调整差异-2.2 天(95%CI-3.1 至-1.2)]。白蛋白浓度在 7 天内下降和未下降的患者对营养支持的反应相似。
这项二次分析的结果表明,营养支持在 7 天内没有增加白蛋白的短期浓度,白蛋白的变化与营养干预的反应无关。然而,白蛋白浓度的增加可能反映了炎症的消退,与更好的临床结局相关。因此,在短期内反复进行住院白蛋白测量以监测接受营养支持的患者并不是必要的,但提供了预后信息。
ClinicalTrials.gov 标识符:NCT02517476。